I-Mab (IMAB)

I-Mab (NASDAQ:IMAB) is a U.S.-based biotechnology company focused on precision immuno-oncology, developing differentiated therapies for cancer.

Jared Holz, the healthcare strategist for Mizuho, spoke on CNBC's "Closing Bell Overtime" in July on whether the biotech industry is ready for a breakthrough.

I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts.

On July 3, Dan Ives, the Global Head of Tech Research at Wedbush, appeared on CNBC to suggest that AI will fuel a multi-year tech rally. Ives stated that he believes they are only at the beginning of...

Operator: Greetings. Welcome to I-MAB Biopharma’s first half 2024 financial results and corporate update conference call. At this time, all participants are in listen-only mode.

Operator: Greetings. Welcome to I-MAB Biopharma’s first half 2024 financial results and corporate update conference call. At this time, all participants are in listen-only mode.

In this article, we discuss Ray Dalio on potential US China war and rise of China.

Tyler Ehler: Good morning, everyone, and thank you for joining us this morning and for standing by.

Tyler Ehler: Good morning to everyone and thank you for joining us this morning. Thank you all for standing by.